A5008291427- Immune cells in cancer
- Phagocytosis and Immune Regulation
- PARP inhibition in cancer therapy
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Glioma Diagnosis and Treatment
- RNA Research and Splicing
- Computational Drug Discovery Methods
- Cancer Genomics and Diagnostics
- Pluripotent Stem Cells Research
- Adenosine and Purinergic Signaling
- Iron Metabolism and Disorders
- Pancreatic and Hepatic Oncology Research
- Atherosclerosis and Cardiovascular Diseases
- Hemoglobinopathies and Related Disorders
- Immunotherapy and Immune Responses
- Cell Adhesion Molecules Research
- CRISPR and Genetic Engineering
- Nanoplatforms for cancer theranostics
- Prostate Cancer Treatment and Research
- Cell death mechanisms and regulation
- Traditional Chinese Medicine Analysis
- Cancer Cells and Metastasis
- Cancer, Lipids, and Metabolism
University of Turku
2015-2024
Ludwig-Maximilians-Universität München
2017
Turku University Hospital
2017
German Centre for Cardiovascular Research
2017
Turku Centre for Biotechnology
2012-2016
Åbo Akademi University
2013-2015
VTT Technical Research Centre of Finland
2012
As foremost regulators of cancer-related inflammation and immunotherapeutic resistance, tumor-associated macrophages have garnered major interest as drug targets. However, depletory strategies yielded little benefit in clinical studies to date. An alternative approach is exploit macrophage plasticity "reeducate" tumorigenic toward an immunostimulatory phenotype activate the host's antitumor immunity.Experimental Design: We investigated role scavenger receptor common lymphatic endothelial...
// Laura Lehtinen 1 , Kirsi Ketola Rami Mäkelä John-Patrick Mpindi 2 Miro Viitala Olli Kallioniemi and Kristiina Iljin Medical Biotechnology, VTT Technical Research Centre of Finland Turku for University Turku, Institute Molecular Medicine (FIMM), Helsinki, Correspondence: Lehtinen, email: Keywords : Breast cancer, vimentin, MTHFD2 Received December 09, 2012, Accepted 15, Published 17, 2012 Abstract Vimentin is an intermediate filament protein, with a key role in the epithelial to...
Early regulators of disease may increase understanding mechanisms and serve as markers for presymptomatic diagnosis treatment. However, early are difficult to identify because patients generally present after they symptomatic. We hypothesized that T cell-associated diseases could be found by identifying upstream transcription factors (TFs) in cell differentiation prioritizing hub TFs were enriched disease-associated polymorphisms. A gene regulatory network (GRN) was constructed time series...
Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell-targeting therapies. Thus, agents able to reprogram macrophages toward a proinflammatory state hold promise as novel immunotherapies for solid cancers. Inhibition macrophage scavenger receptor Clever-1 has shown benefit inducing CD8
Low oxygen tension (hypoxia) contributes critically to pluripotency of human embryonic stem cells (hESCs) by preventing spontaneous differentiation and supporting self-renewal. However, it is not well understood how hESCs respond reduced availability what are the molecular mechanisms maintaining in these conditions. In this study we characterized transcriptional responses three hESC lines (H9, HS401 HS360) on short (2 hours), intermediate (24 hours) prolonged (7 days) exposure low conditions...
The RNA-binding protein L1TD1 is one of the most specific and abundant proteins in pluripotent stem cells essential for maintenance pluripotency human cells. Here, we identify interaction network embryonic (hESCs) provide insights into interactome constructed Our data reveal that has an important role RNA splicing, translation, traffic, degradation. interacts with multiple stem-cell-specific proteins, many which are still uncharacterized context development. Further, show a part OCT4, SOX2,...
The MC1-R (melanocortin 1 receptor) is expressed by monocytes and macrophages where it mediates anti-inflammatory actions. also protects against macrophage foam cell formation primarily promoting cholesterol efflux through the ABCA1 (ATP-binding cassette transporter subfamily A member 1) ABCG1 G 1). In this study, we aimed to investigate whether global deficiency in signaling affects development of atherosclerosis. Apoe-/- (apolipoprotein E deficient) mice were crossed with recessive yellow...
Clever-1, encoded by the Stab1 gene, is a scavenger and leukocyte trafficking receptor expressed subsets of vascular lymphatic endothelial cells immunosuppressive macrophages. Monocyte Clever-1 also modulates T cell activation. However, nothing known about possible links between B function Clever-1. Here, we found that knockout mice (Stab1−/−) lacking protein from all present with abnormally high antibody levels under resting conditions show enhanced humoral immune responses after...
Abstract Clever-1 functions as a scavenger and adhesion receptor, promoting tolerogenic activities in macrophages subsets of endothelial cells, thereby contributing to cancer progression. High expression associates with resistance immune checkpoint inhibitors combined targeting anti-PD-1 enhances response refractory mouse tumor models. A Clever-1–targeting humanized IgG4 antibody, bexmarilimab, is investigated clinical trials macrophage-reprogramming therapy treat solid tumors ( NCT03733990...
<div>AbstractPurpose:<p>Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell–targeting therapies. Thus, agents able to reprogram macrophages toward a proinflammatory state hold promise as novel immunotherapies for solid cancers. Inhibition macrophage scavenger receptor Clever-1 has shown benefit inducing CD8<sup>+</sup> T-cell–mediated antitumor responses mouse models cancer, which supports clinical...
<p>Excel spreadsheets of mass spectrometry analysis</p>
<p>Supplementary Figures</p>
<p>Excel spreadsheet of differentially expressed genes in CD14+ monocytes</p>
<div>AbstractPurpose:<p>Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell–targeting therapies. Thus, agents able to reprogram macrophages toward a proinflammatory state hold promise as novel immunotherapies for solid cancers. Inhibition macrophage scavenger receptor Clever-1 has shown benefit inducing CD8<sup>+</sup> T-cell–mediated antitumor responses mouse models cancer, which supports clinical...
<p>Tables</p>
<p>Tables</p>
<p>Supplementary Figures</p>
<p>Excel spreadsheets of mass spectrometry analysis</p>
<p>Excel spreadsheet of differentially expressed genes in CD14+ monocytes</p>
Abstract Macrophages are considered the main obstacles for successful cancer treatment since they can dampen anti-tumor immune responses and promote tumor progression resistance formation. highly eligible candidates targeted therapies these cells abundantly present in various tumors, very plastic be converted into pro-inflammatory macrophages supporting T cell activation rejection. Clever-1 (also known as Stabilin-1) is a multifunctional molecule conferring scavenging ability on subset of...
Abstract Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell targeting therapies. Thus, agents can reprogram macrophages towards a proinflammatory state hold promise as novel immunotherapies for solid cancers. Here, we report immunotherapeutic macrophage scavenger receptor Clever-1 heavily pretreated metastatic cancer patients was able to induce significant increase and activation peripheral T-cells. Anti-Clever-1 (FP-1305)...
<p>Supplementary figures</p>